Trial Profile
Phase 2 Trial of Induction With Ixazomib, Pomalidomide, Dexamethasone Prior to Salvage Autologous Stem Cell Transplant Followed by Consolidation With Ixazomib, Pomalidomide, and Dexamethasone and Ixazomib Maintenance in Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Jun 2023 Status changed from active, no longer recruiting to completed.
- 14 Jul 2022 Planned End Date changed from 24 Jul 2022 to 24 Jul 2023.
- 06 Apr 2021 Planned primary completion date changed from 24 Jul 2022 to 1 May 2021.